467 related articles for article (PubMed ID: 36814688)
1. Targeted therapy for pancreatic ductal adenocarcinoma: Mechanisms and clinical study.
Kung HC; Yu J
MedComm (2020); 2023 Apr; 4(2):e216. PubMed ID: 36814688
[TBL] [Abstract][Full Text] [Related]
2. Targeted Therapy for Highly Desmoplastic and Immunosuppressive Tumor Microenvironment of Pancreatic Ductal Adenocarcinoma.
Olaoba OT; Yang M; Adelusi TI; Maidens T; Kimchi ET; Staveley-O'Carroll KF; Li G
Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672552
[TBL] [Abstract][Full Text] [Related]
3. Enhanced Complement Expression in the Tumor Microenvironment Following Neoadjuvant Therapy: Implications for Immunomodulation and Survival in Pancreatic Ductal Adenocarcinoma.
Zhang X; Lan R; Liu Y; Pillarisetty VG; Li D; Zhao CL; Sarkar SA; Liu W; Hanna I; Gupta M; Hajdu C; Melamed J; Shusterman M; Widmer J; Allendorf J; Liu YZ
Res Sq; 2024 May; ():. PubMed ID: 38798691
[TBL] [Abstract][Full Text] [Related]
4. Regulatory role of RNA modifications in the treatment of pancreatic ductal adenocarcinoma (PDAC).
Chen H; Luo W; Lu X; Zhang T
Heliyon; 2023 Nov; 9(11):e20969. PubMed ID: 37928039
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant treatment: A window of opportunity for nutritional prehabilitation in patients with pancreatic ductal adenocarcinoma.
Trestini I; Cintoni M; Rinninella E; Grassi F; Paiella S; Salvia R; Bria E; Pozzo C; Alfieri S; Gasbarrini A; Tortora G; Milella M; Mele MC
World J Gastrointest Surg; 2021 Sep; 13(9):885-903. PubMed ID: 34621468
[TBL] [Abstract][Full Text] [Related]
6. Ion Channels Orchestrate Pancreatic Ductal Adenocarcinoma Progression and Therapy.
Hofschröer V; Najder K; Rugi M; Bouazzi R; Cozzolino M; Arcangeli A; Panyi G; Schwab A
Front Pharmacol; 2020; 11():586599. PubMed ID: 33841132
[TBL] [Abstract][Full Text] [Related]
7. Unveiling the immunosuppressive landscape of pancreatic ductal adenocarcinoma: implications for innovative immunotherapy strategies.
Guo S; Wang Z
Front Oncol; 2024; 14():1349308. PubMed ID: 38590651
[TBL] [Abstract][Full Text] [Related]
8. Neutrophils in pancreatic ductal adenocarcinoma: bridging preclinical insights to clinical prospects for improved therapeutic strategies.
Jin Y; Christenson ES; Zheng L; Li K
Expert Rev Clin Immunol; 2024 May; ():1-14. PubMed ID: 38690749
[TBL] [Abstract][Full Text] [Related]
9. Clinical and Preclinical Targeting of Oncogenic Pathways in PDAC: Targeted Therapeutic Approaches for the Deadliest Cancer.
Jiménez DJ; Javed A; Rubio-Tomás T; Seye-Loum N; Barceló C
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474109
[TBL] [Abstract][Full Text] [Related]
10. Overcoming the Tumor Microenvironmental Barriers of Pancreatic Ductal Adenocarcinomas for Achieving Better Treatment Outcomes.
Alzhrani R; Alsaab HO; Vanamal K; Bhise K; Tatiparti K; Barari A; Sau S; Iyer AK
Adv Ther (Weinh); 2021 Jun; 4(6):. PubMed ID: 34212073
[TBL] [Abstract][Full Text] [Related]
11. Precision treatment of pancreatic ductal adenocarcinoma.
Wei H; Ren H
Cancer Lett; 2024 Mar; 585():216636. PubMed ID: 38278471
[TBL] [Abstract][Full Text] [Related]
12. The Latest Advancement in Pancreatic Ductal Adenocarcinoma Therapy: A Review Article for the Latest Guidelines and Novel Therapies.
Elsayed M; Abdelrahim M
Biomedicines; 2021 Apr; 9(4):. PubMed ID: 33917380
[TBL] [Abstract][Full Text] [Related]
13. Driver Mutations in Pancreatic Cancer and Opportunities for Targeted Therapy.
Olaoba OT; Adelusi TI; Yang M; Maidens T; Kimchi ET; Staveley-O'Carroll KF; Li G
Cancers (Basel); 2024 May; 16(10):. PubMed ID: 38791887
[TBL] [Abstract][Full Text] [Related]
14. Exploring the Role of Desmoplastic Physical Stroma in Pancreatic Cancer Progression Using a Three-Dimensional Collagen Matrix Model.
Song X; Nihashi Y; Yamamoto M; Setoyama D; Kunisaki Y; Kida YS
Bioengineering (Basel); 2023 Dec; 10(12):. PubMed ID: 38136028
[TBL] [Abstract][Full Text] [Related]
15. Molecular therapeutics in pancreas cancer.
Narayanan V; Weekes CD
World J Gastrointest Oncol; 2016 Apr; 8(4):366-79. PubMed ID: 27096032
[TBL] [Abstract][Full Text] [Related]
16. Hydrogel-Based Therapeutics for Pancreatic Ductal Adenocarcinoma Treatment.
Liu J; Wu W; Zhu Q; Zhu H
Pharmaceutics; 2023 Oct; 15(10):. PubMed ID: 37896181
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant Immunotherapy for Localized Pancreatic Cancer: Challenges and Early Results.
Chick RC; Gunderson AJ; Rahman S; Cloyd JM
Cancers (Basel); 2023 Aug; 15(15):. PubMed ID: 37568782
[TBL] [Abstract][Full Text] [Related]
18. Isolated lung metastases from pancreatic ductal adenocarcinoma (PDAC): Diagnostic and therapeutic challenges of a different disease.
Giulia O; Alessandro B; Angelo C; Paolo M; Rosa C; Marina M; Umberto P; Catia C; Giulia V; Massimo F; Michele R
Semin Oncol; 2024 May; ():. PubMed ID: 38879350
[TBL] [Abstract][Full Text] [Related]
19. Microscopic tumor mapping of post-neoadjuvant therapy pancreatic cancer specimens to predict post-surgical recurrence: A prospective cohort study.
Park Y; Han YB; Kim J; Kang M; Lee B; Ahn ES; Han S; Kim H; Na HY; Han HS; Yoon YS
Pancreatology; 2024 Jun; 24(4):562-571. PubMed ID: 38556428
[TBL] [Abstract][Full Text] [Related]
20. Genetic and other risk factors for pancreatic ductal adenocarcinoma (PDAC).
Jacobs MF; Stoffel EM
Fam Cancer; 2024 Apr; ():. PubMed ID: 38573398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
